Taro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings results on Thursday. The company reported $2.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.66, Fidelity Earnings reports. Taro Pharmaceutical Industries had a net margin of 30.43% and a return on equity of 11.35%. The business had revenue of $175.22 million for the quarter, compared to the consensus estimate of $166.59 million.
NYSE TARO traded down $2.03 during trading hours on Friday, reaching $113.50. The company’s stock had a trading volume of 1,644 shares, compared to its average volume of 84,169. The firm has a market cap of $4.54 billion, a PE ratio of 10.31 and a beta of 0.62. Taro Pharmaceutical Industries has a 52 week low of $112.42 and a 52 week high of $113.00.
A number of equities research analysts have issued reports on TARO shares. HC Wainwright set a $124.00 price objective on shares of Taro Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Tuesday. ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $124.00.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.